Stephen C. Glover - 18 May 2023 Form 4 Insider Report for Ambrx Biopharma Inc.

Role
Director
Signature
/s/ Sonja Nelson, Attorney-in-Fact for Stephen Glover
Issuer symbol
N/A
Transactions as of
18 May 2023
Net transactions value
$0
Form type
4
Filing time
26 May 2023, 20:20:00 UTC
Previous filing
13 Dec 2022
Next filing
18 Jul 2024
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Stephen C. Glover filed Form 4 for Ambrx Biopharma Inc. on 26 May 2023."

Quick Takeaways

  • This page summarizes Stephen C. Glover's Form 4 filing for Ambrx Biopharma Inc..
  • 1 reported transaction and 1 derivative row are listed below.
  • Filing timestamp: 26 May 2023, 20:20.

What Changed

  • Previous filing in this sequence was filed on 13 Dec 2022.
  • Current net transaction value: $0.

Why This Matters

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Official SEC Source

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMAM Stock Option (right to buy) Award $0 +210,000 $0.000000 210,000 18 May 2023 Ordinary Shares 210,000 $1.97 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The exercise price of the options is equal to the fair market value per ordinary share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs").
F2 The Ordinary Shares subject to the option vest in thirty-six (36) equal monthly installments following May 19, 2023.
F3 The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents seven (7) Ordinary Shares of the Issuer.

Sponsored